Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.

RATIONALE AND OBJECTIVES The aim of this study was to assess the role of diffusion-weighted imaging in predicting progression-free survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with induction chemotherapy. MATERIALS AND METHODS Eighteen patients with HNSCC underwent diffusion-weighted imaging studies prior to treatment and within 3 weeks after completion of induction chemotherapy. Median apparent diffusion coefficient (ADC) values were computed from the largest cervical metastatic lymph node. Percentage changes in ADC values from pretreatment to posttreatment time points were compared between alive and dead patients using the Mann-Whitney U test. P values < .05 were considered statistically significant. RESULTS A 22% increase in ADC was observed after induction chemotherapy in alive patients (n = 15), while patients who died from HNSCC (n = 3) demonstrated a 33% decrease in ADC. The difference in percentage change in ADC between alive and dead patients was significant (P = .039). CONCLUSIONS ADC may be a useful marker in predicting progression-free survival in patients with HNSCC undergoing induction chemotherapy.

[1]  H. Thames,et al.  Tumor volume: a basic and specific response predictor in radiotherapy. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  T. Bezabeh,et al.  Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy. , 2005, AJNR. American journal of neuroradiology.

[3]  U. Sharma,et al.  Longitudinal study of the assessment by MRI and diffusion‐weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2009, NMR in biomedicine.

[4]  G. Weinstein,et al.  Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck , 2009, Clinical Cancer Research.

[5]  B. Fallone,et al.  Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model , 2010, Physics in medicine and biology.

[6]  R. Hermans,et al.  Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma , 2010, European Radiology.

[7]  T. Cloughesy,et al.  Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma , 1999, Magnetic resonance in medicine.

[8]  A. Razek,et al.  Role of Diffusion-Weighted Echo-Planar MR Imaging in Differentiation of Residual or Recurrent Head and Neck Tumors and Posttreatment Changes , 2007, American Journal of Neuroradiology.

[9]  G. Calais,et al.  Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Chenevert,et al.  Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. , 2008, Translational oncology.

[11]  T. Wendt,et al.  Prognostic Factors in Squamous Cell Carcinoma of the Head and Neck , 2002, Oncology Research and Treatment.

[12]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[13]  Ruth C Carlos,et al.  Computed Tomography Perfusion of Squamous Cell Carcinoma of the Upper Aerodigestive Tract: Initial Results , 2003, Journal of computer assisted tomography.

[14]  D J Brenner,et al.  Dose, volume, and tumor-control predictions in radiotherapy. , 1993, International journal of radiation oncology, biology, physics.

[15]  B. Fallone,et al.  Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy. , 2009, Medical physics.

[16]  Tim Baker,et al.  Economic burden of heart failure: a summary of recent literature. , 2004, Heart & lung : the journal of critical care.

[17]  K. Hayashi,et al.  Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. , 2003, AJNR. American journal of neuroradiology.

[18]  K. Ang,et al.  Head and Neck Cancers , 2011 .

[19]  K. Frey,et al.  Advanced squamous cell carcinoma of the oropharynx: Efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy , 2009, Head & neck.

[20]  F. Hoebers,et al.  Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer , 2010, Head & neck.

[21]  M. Kanematsu,et al.  Head and neck squamous cell carcinoma: usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect , 2008, European Radiology.

[22]  S. Takashima,et al.  Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. , 2001, Radiology.

[23]  H. Minn,et al.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  À. Rovira,et al.  31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. , 1998, International journal of radiation oncology, biology, physics.

[25]  J. Jacobs,et al.  Correlation between response to cisplatinum‐combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck , 1984, Cancer.

[26]  S. Mukherji,et al.  Differentiation of Benign and Malignant Pathology in the Head and Neck Using 3T Apparent Diffusion Coefficient Values: Early Experience , 2008, American Journal of Neuroradiology.

[27]  A. Ruifrok,et al.  Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Risto A Kauppinen,et al.  Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy , 2002, NMR in biomedicine.

[29]  James M Provenzale,et al.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.

[30]  J. Vermorken,et al.  Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? , 2007, Cancer letters.

[31]  G. Weinstein,et al.  Prediction of Response to Chemoradiation Therapy in Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging , 2010, American Journal of Neuroradiology.

[32]  Ann D. King,et al.  Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response , 2010, European Radiology.

[33]  J. Vermorken,et al.  Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. , 2008, Seminars in oncology.

[34]  Mark Rijpkema,et al.  Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. , 2002, Academic radiology.

[35]  M. Fury,et al.  Induction chemotherapy in the management of head and neck cancer , 2010, Journal of surgical oncology.

[36]  R. Bast,et al.  Principles of Medical Oncology , 2003 .

[37]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  R. Gillies,et al.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. , 1999, Neoplasia.

[39]  Sandra Nuyts,et al.  Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. , 2007, International journal of radiation oncology, biology, physics.

[40]  J. Pipe,et al.  Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. , 1996, British Journal of Cancer.

[41]  M. Leblanc,et al.  FDG-PET prediction of head and neck squamous cell cancer outcomes. , 2004, Archives of otolaryngology--head & neck surgery.

[42]  A. Garden,et al.  Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? , 2004, Cancer.

[43]  Philippe Lambin,et al.  Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[44]  J. Griffiths,et al.  The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. , 2006, Neoplasia.

[45]  A. Razek,et al.  Role of diffusion-weighted magnetic resonance imaging in differentiation between the viable and necrotic parts of head and neck tumors , 2008, Acta radiologica.

[46]  R. Kauppinen,et al.  Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. , 1998, Cancer gene therapy.

[47]  K. Kihara,et al.  Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. , 2010, Urology.